What are you looking for?
Dengue is one of the most rapidly spreading infectious diseases worldwide. Between 2000 and 2019, the number of cases increased tenfold. Today, half of the world’s population lives in areas where dengue is endemic1.
One of the reasons for this is the global warming, which greatly favours the spread of the tiger mosquitoes (Aedes aegypti and Aedes albopictus) that act as vectors for dengue. In many endemic areas, the rising temperatures and heavier rainfall associated with climate change are contributing to an increase in the number of mosquitoes2.
1 WHO: Dengue and severe dengue; Dengue - Global situation as of 21 December 2023
2 WHO: Dengue - Global situation as of 30 May 2024
Specifically for dengue virus infection, we offer you diagnostic solutions for all stages of the disease – from the onset of the first symptoms to the end of the disease.
Other relevant arboviral parameters:
You're invited to "Today's Clinical Lab Infectious Disease & Antimicrobial Resistance Digital Forum" event!
Register for free and view the on-demand presentation of the EUROIMMUN session "Dengue Infection: Effective Strategies for Accurate Detection During Global Surge" from July 9, 2024.
Thinking globally – acting locally
With over 35 years of experience in the field of laboratory diagnostics, we develop and globally distribute complete diagnostic solutions that are tailored to your local needs. Working together with local health and scientific authorities we stay aware of novel and/or urgent infection events and deliver appropriate solutions for infectious diseases diagnostics all over the world. With our unrivalled in-house development and production of diagnostic test systems as well as our automation and software solutions, we are able to respond rapidly to both small and large infection outbreaks, providing support to national and international health entities when and where it is needed.
Thinking globally – acting locally
Adapted from Ohst C et al.,
Reliable serological testing for the diagnosis of emerging infectious diseases. Adv Exp Med Biol 1062:19-43 (2018).
Detection of the viral protein NS1 as early marker of acute infection as well as antibody detection for the identification of acute and past infections.
Antibody detection for the identification of acute and past infections as well as screening and investigation of cross reactions.
Find out more about our test portfolio
Our products make a valuable contribution not only to diagnostics, but also to screening prior to vaccination with the first dengue vaccine, which was launched in 2015*.
This is because the CYD-TDV vaccine (Dengvaxia) is only given to people living in endemic areas who have been confirmed to have been infected with dengue virus. The CDC (Centers for Disease Control and Prevention) therefore recommends double testing with two specific test systems for the detection of IgG antibodies against dengue. One of the two test systems of this two-step algorithm is the EUROIMMUN Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG)3.
3 CDC: Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue Vaccine
Qdenga, another vaccine against dengue, has been available since 2022*. Further vaccines are currently in development.
* Approval dates vary depending on the country
If you have any questions, please do not hesitate to contact us:
Or get in touch with your local contact person
Find your local distributor
EUROIMMUN offers an extensive range of test systems for infection diagnostics, including serological
assays for antibody determination and PCR-based tests for direct pathogen detection. For the growing
field of emerging diseases, EUROIMMUN boasts one of the largest portfolios of antibody tests
worldwide to support diagnosis and surveillance of upsurging viral and parasitic infections.
Read more
Featured in PPC, April 2024